KNSA
Kiniksa Pharmaceuticals, Ltd.
NASDAQ · Healthcare · Biotechnology · BM
$77.91
−3.18%Year over year
Reported trailing growth
- Revenue
- +58.9%
- EBITDA
- +742.4%
- EBIT
- +2140.2%
- EPS
- +1683.3%
- Free cash flow
- +175.4%
- Operating cash flow
- +176.7%
Forward estimates
Based on analyst estimates
- Revenue
- +34.5%
- EBITDA
- +75.1%
- EPS
- +48.3%
Three-year CAGR
- Revenue
- +45.5%
- EBITDA
- +88.8%
- EBIT
- +99.2%
- Net income
- -31.5%
- EPS
- -32.8%
- Free cash flow
- +64.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026